Last reviewed · How we verify
somatostatin or terlipressin
Somatostatin and terlipressin are vasoactive peptides that bind to somatostatin receptors and vasopressin receptors respectively, reducing splanchnic blood flow and portal pressure.
Somatostatin and terlipressin are vasoactive peptides that bind to somatostatin receptors and vasopressin receptors respectively, reducing splanchnic blood flow and portal pressure. Used for Acute variceal bleeding in portal hypertension, Prevention of variceal rebleeding.
At a glance
| Generic name | somatostatin or terlipressin |
|---|---|
| Also known as | somatostatin and terlipressin are vasoconstrictors. |
| Sponsor | National Science and Technology Council, Taiwan |
| Drug class | Vasoactive peptide |
| Target | Somatostatin receptors (SSTR) / Vasopressin V1 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Somatostatin is a naturally occurring inhibitory peptide that binds to somatostatin receptors (SSTR1-5) on vascular smooth muscle and endothelial cells, causing vasoconstriction of splanchnic vessels and reducing portal venous inflow. Terlipressin is a selective vasopressin V1 receptor agonist that causes systemic and splanchnic vasoconstriction, increasing systemic vascular resistance and reducing portal pressure. Both agents are used acutely to control variceal bleeding by decreasing portal hypertension.
Approved indications
- Acute variceal bleeding in portal hypertension
- Prevention of variceal rebleeding
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Hypertension
- Cardiac arrhythmias
- Ischemic complications
Key clinical trials
- Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis (NA)
- Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (NA)
- Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage
- Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis (NA)
- TIPS in Fundal Variceal Bleeding (the TFB Study) (NA)
- Vasoactive Drugs in Real World Practice (PHASE4)
- Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails
- EVL (Endoscopic Variceal Ligation) Plus Vasoconstrictor vs.Ligation Plus PPI( Proton Pump Inhibitor) in the Control of Acute Esophageal Variceal Bleeding (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |